Codexis Inc/ US1920051067 /
5/28/2024 10:00:00 PM | Chg. -0.0200 | Volume | Bid11:09:06 PM | Ask11:09:06 PM | High | Low |
---|---|---|---|---|---|---|
3.1500USD | -0.63% | 223,020 Turnover: 591,877.5104 |
2.9000Bid Size: 200 | 3.4600Ask Size: 1,000 | 3.2200 | 3.0900 |
GlobeNewswire
5/14
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
GlobeNewswire
5/6
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
2/26
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
2/20
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
GlobeNewswire
2/14
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
GlobeNewswire
2/13
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further S...
GlobeNewswire
2/1
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT Genera...
GlobeNewswire
12/27/2023
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
GlobeNewswire
12/13/2023
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
GlobeNewswire
12/13/2023
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
GlobeNewswire
12/11/2023
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeuti...
GlobeNewswire
11/28/2023
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics...